Cadrenal Therapeutics (CVKD) News Today $16.17 +1.68 (+11.59%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cadrenal Therapeutics (NASDAQ:CVKD) Stock Price Up 11.6% - Here's What HappenedDecember 21 at 2:25 AM | americanbankingnews.comCadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner MeetingsDecember 18 at 6:00 PM | finance.yahoo.comCVKD: Recent Financings Raise $9.8 Million…November 20, 2024 | msn.comCadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech OutlookNovember 19, 2024 | prnewswire.comCadrenal Therapeutics files to sell 590K shares of common stock for holdersNovember 15, 2024 | markets.businessinsider.comCADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESSNovember 12, 2024 | prnewswire.comCadrenal Therapeutics Advances Tecarfarin DevelopmentNovember 9, 2024 | markets.businessinsider.comCADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATENovember 7, 2024 | prnewswire.comCadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross ProceedsNovember 1, 2024 | prnewswire.comWe're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn RateOctober 29, 2024 | finance.yahoo.comPonte Vedra pharmaceutical company raises $5.1 millionOctober 24, 2024 | bizjournals.comCadrenal Therapeutics raises $5.1M via at-the-market facilityOctober 24, 2024 | markets.businessinsider.comCadrenal Therapeutics Raises $5.1 Million for TecarfarinOctober 24, 2024 | markets.businessinsider.comCadrenal Therapeutics Raises $5.1 Million via At-The-Market FacilityOctober 24, 2024 | prnewswire.comCADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUMOctober 23, 2024 | prnewswire.comCadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Large Decline in Short InterestCadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 18,000 shares, a decrease of 7.2% from the September 15th total of 19,400 shares. Based on an average daily volume of 32,500 shares, the short-interest ratio is currently 0.6 days. Approximately 3.2% of the company's shares are short sold.October 17, 2024 | marketbeat.comCadrenal Therapeutics, Inc. (NASDAQ:CVKD) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) by 59.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 59,491 shares of the company's stock after selling 88,647 sharOctober 15, 2024 | marketbeat.comCadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Significant Increase in Short InterestCadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 19,400 shares, a growth of 22.8% from the August 31st total of 15,800 shares. Approximately 3.4% of the company's stock are short sold. Based on an average daily volume of 25,600 shares, the short-interest ratio is currently 0.8 days.September 30, 2024 | marketbeat.comCadrenal Therapeutics (NASDAQ:CVKD) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comCadrenal Therapeutics (NASDAQ:CVKD) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comCadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor ConferenceSeptember 23, 2024 | prnewswire.comZacks Small Cap Comments on Cadrenal Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) - Equities researchers at Zacks Small Cap issued their Q3 2024 EPS estimates for Cadrenal Therapeutics in a note issued to investors on Monday, September 16th. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of (September 18, 2024 | marketbeat.comCVKD: New Blood Thinner Ready for Phase 3; Initiating Coverage of Cadrenal Therapeutics, Inc…September 16, 2024 | msn.comCadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest UpdateCadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 15,800 shares, an increase of 295.0% from the August 15th total of 4,000 shares. Based on an average daily volume of 20,200 shares, the short-interest ratio is presently 0.8 days. Approximately 2.8% of the shares of the company are short sold.September 12, 2024 | marketbeat.comCadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsAugust 22, 2024 | prnewswire.comPublished Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD PatientsAugust 20, 2024 | prnewswire.comCadrenal Therapeutics to Present at Upcoming Investor ConferencesAugust 14, 2024 | prnewswire.comCVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD PatientsAugust 7, 2024 | msn.comCadrenal Therapeutics Provides Second Quarter 2024 Corporate UpdateAugust 7, 2024 | prnewswire.comCadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADsAugust 6, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024July 17, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024June 11, 2024 | prnewswire.comCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsJune 3, 2024 | prnewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 23, 2024 | prnewswire.comBuy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial ProspectsMay 10, 2024 | markets.businessinsider.comCadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateMay 9, 2024 | prnewswire.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockApril 20, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | prnewswire.comCadrenal Therapeutics Gets FDA Orphan Drug Designation for TecarfarinApril 11, 2024 | marketwatch.comCadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock JumpsApril 9, 2024 | markets.businessinsider.comPonte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designationApril 9, 2024 | bizjournals.comCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsApril 9, 2024 | prnewswire.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 14, 2024 | markets.businessinsider.comCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finanznachrichten.deCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceFebruary 26, 2024 | prnewswire.comCadrenal Therapeutics Inc CVKDFebruary 14, 2024 | morningstar.comCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialFebruary 8, 2024 | finanznachrichten.deCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialFebruary 8, 2024 | finance.yahoo.com Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. CVKD Media Mentions By Week CVKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVKD News Sentiment▼0.000.60▲Average Medical News Sentiment CVKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVKD Articles This Week▼21▲CVKD Articles Average Week Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UNCY News Today PDSB News Today EPIX News Today VOR News Today ANVS News Today VTGN News Today OPTN News Today RPTX News Today BCAB News Today DBVT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CVKD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
